E-cigarettes are almost twice as effective as nicotine replacement treatments, such as patches and gum, at helping smokers to quit, according to a clinical trial led by Queen Mary University of London.
The multi-centre trial, which involved almost 900 smokers who also received additional behavioural support, found that 18.0 per cent of e-cigarette users were smoke-free after a year, compared to 9.9 per cent of participants who were using other nicotine replacement therapies.
Lead researcher Professor Peter Hajek from Queen Mary University of London said: "This is the first trial to test the efficacy of modern e-cigarettes in helping smokers quit. E-cigarettes were almost twice as effective as the 'gold standard' combination of nicotine replacement products.
"Although a large number of smokers report that they have quit smoking successfully with the help of e-cigarettes, health professionals have been reluctant to recommend their use because of the lack of clear evidence from randomised controlled trials. This is now likely to change."
The only previous trial comparing e-cigarettes to nicotine patches used early 'cig-a-like' e-cigarettes with very low nicotine delivery, had no face-to-face contact, and found low efficacies for both treatments.
Funded by the National Institute for Health Research, supported by Cancer Research UK and published in the New England Journal of Medicine, the new study, was set-up to test the long-term efficacy of newer refillable e-cigarettes compared with a range of nicotine replacement treatments
886 smokers attended UK National Health Service stop smoking services (in Tower Hamlets, City of London, Leicester and East Sussex) and were randomised to receive either a nicotine replacement treatment of their choice (including patches, gum, lozenges, sprays, inhalators, or a combination of products) provided for up to three months, or an e-cigarette starter pack with one or two bottles of e-liquid and encouragement to buy future supplies of their own choice of strengths and flavours.
All participants received weekly one-on-one behavioural support for at least four weeks, with expired air carbon monoxide monitoring.
In addition to e-cigarettes being almost twice as effective, the researchers found that:
- The participants comprised largely of middle aged dependent smokers, with 40 per cent entitled to free prescriptions (a marker of social disadvantage or poor health)
- Abstinence rates were higher in the e-cigarette arm at all time points
- Among abstainers, e-cigarette participants were more likely to use their allocated product at 52 weeks than nicotine replacement participants (79.8 per cent vs 9.1 per cent)
- Among participants who did not achieve full abstinence, more e-cigarette users achieved a carbon monoxide-validated reduction of smoking by at least 50 per cent
- Adherence was similar in both arms, but e-cigarettes were used more frequently and for longer
- E-cigarette participants reported more throat/mouth irritation (65.4 per cent vs 50.8 per cent) and nicotine replacement participants reported more nausea (37.8 per cent vs 31.4 per cent)
- E-cigarette participants reported greater decline in incidence of cough and phlegm production after 52 weeks
- Both products were perceived as less satisfying than cigarettes, but e-cigarettes provided higher satisfaction and were rated as more helpful than nicotine replacement treatment
- E-cigarette arm abstainers experienced less severe urges to smoke at 1 and 4 weeks post-quit date. They also reported a lower increase in irritability, restlessness and inability to concentrate after the first week of abstinence, compared to those in the nicotine replacement arm
Study author Dunja Przulj from Queen Mary University of London said: "The UK specialist stop smoking services will now be more likely to include e-cigarettes among their treatment options, and health professionals will feel more comfortable in recommending e-cigarettes as a stop-smoking intervention. This may ultimately further accelerate the reduction in smoking and in smoking related diseases."
Professor Hywel Williams, Director of the NIHR Health Technology Assessment Programme, said: "This groundbreaking NIHR-funded study provides clear evidence that e-cigarettes are almost twice as effective as nicotine replacement therapy for helping smokers to quit. Cigarette smoking is still a major cause of ill health and death in the UK, so this study will provide much needed evidence to help people and policy makers to make informed choices."
Martin Dockrell, Tobacco Control Lead, Public Health England, said: "This landmark research shows that switching to an e-cigarette can be one of the most effective ways to quit smoking, especially when combined with face-to-face support. All stop smoking services should welcome smokers who want to quit with the help of an e-cigarette."
The study saw a stronger e-cigarette effect than in previous trials, and the researchers say this could be due to the inclusion of smokers who were seeking help, the provision of face-to-face support, and the use of refillable e-cigarettes for which smokers sourced their own choice of e-liquids.
The researchers add that the reason e-cigarettes were found to be more effective than other nicotine replacement therapies could be primarily because they allow better tailoring of nicotine dose to individual needs, but also because they provide some of the behavioural aspects of smoking cigarettes.
The study has several limitations. Product allocation could not be blinded, which could affect results if nicotine replacement was seen as an inferior option and those participants were putting less effort into their quit attempt. The team tried to limit expectation effects by recruiting only participants with no strong product preference, and the results in the nicotine replacement arm were at least as good as in routine practice.
The findings may not be generalisable to smokers who are less dependent, or to first generation 'cig-a-like' e-cigarettes, and further trials are needed to determine whether the results generalise outside the UK services.
Sophia Lowes, from Cancer Research UK, said: "This is the first study to show the effectiveness of e-cigarettes combined with behavioural support for giving up smoking, and the results are extremely positive. This research should give doctors, nurses, pharmacists and Stop Smoking Service advisers further confidence to recommend e-cigarettes as an effective means of quitting.
"Smokers have a range of options available to help them quit, including nicotine replacement therapy, prescription medication or e-cigarettes. Everyone is different, so smokers shouldn't be afraid to experiment and find what works for them. But whatever the method, it's clear that using the support available from local Stop Smoking Services gives smokers the best chance of quitting."
For more information, please contact:
Public Relations Manager (School of Medicine and Dentistry)
Queen Mary University of London
Tel: +44 (0)20 7882 7943 / +44 (0)7970 096 188
Notes to the editor
Research paper: 'A randomised trial of e-cigarettes versus nicotine replacement therapy'. Peter Hajek, PhD, Anna Phillips-Waller, BSc, Dunja Przulj, PhD, Francesca Pesola, PhD, Katie Myers Smith, DPsych, Natalie Bisal, MSc, Jinshuo Li, MPhil, Steve Parrott, MSc, Peter Sasieni, PhD, Lynne Dawkins, PhD, Louise. Ross, Maciej Goniewicz, PhD, PharmD, Qi Wu, MSc, Hayden James McRobbie, PhD. New England Journal of Medicine. DOI: 10.1056/NEJMoa1808779
Available here after the embargo lifts: https:/
About Queen Mary University of London
Queen Mary University of London is a world-leading research-intensive university with over 25,000 students representing more than 160 nationalities.
A member of the prestigious Russell Group, we work across the humanities and social sciences, medicine and dentistry, and science and engineering, with inspirational teaching directly informed by our research.
In the most recent exercise that rated research in the UK, we were ranked 5th in the country for the proportion of research outputs that were world-leading or internationally excellent. We offer more than 240 degree programmes and our reputation for excellent teaching was rewarded with a silver in the 2017 Teaching Excellence Framework (TEF) awards.
Queen Mary's history dates back to 1785, with the foundation of the London Hospital Medical College. Our history also encompasses the establishment of the People's Palace in 1887, which brought accessible education, culture and recreation to the East End of London. We also have roots in Westfield College, one of the first colleges to provide higher education to women.
About the National Institute for Health Research
The National Institute for Health Research (NIHR) is the nation's largest funder of health and care research. The NIHR:
- Funds, supports and delivers high quality research that benefits the NHS, public health and social care
- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy
The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR commissions applied health research to benefit the poorest people in low- and middle-income countries, using Official Development Assistance funding.
This work uses data provided by patients and collected by the NHS as part of their care and support and would not have been possible without access to this data. The NIHR recognises and values the role of patient data, securely accessed and stored, both in underpinning and leading to improvements in research and care. http://www.